Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lenvima 10 mg Alternative – Lenvaxen (Lenvatinib) 10 mg Capsule | Everest Pharmaceuticals
Lenvaxen 10 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 10 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lenvima 4 mg Alternative – Lenvaxen (Lenvatinib) 4 mg Capsule | Everest Pharmaceuticals
Lenvaxen 4 mg (Lenvatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lenvima (Eisai). It belongs to the multikinase inhibitor class and is used in selected thyroid, renal, liver and endometrial cancer regimens.
Active ingredient: Lenvatinib
Strength: 4 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lonsurf 15 mg / 6.14 mg Alternative – Trifluxen (Trifluridine 15 mg + Tipiracil 6.14 mg) 15 mg / 6.14 mg Tablet | Everest Pharmaceuticals
Trifluxen 15 mg / 6.14 mg (Trifluridine 15 mg + Tipiracil 6.14 mg) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lonsurf (Taiho Oncology). It belongs to the trifluridine/tipiracil combination class and is used in selected previously treated metastatic colorectal cancer and other authorized settings.
Active ingredient: Trifluridine 15 mg + Tipiracil 6.14 mg
Strength: 15 mg / 6.14 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lynparza 150 mg Alternative – Olanib (Olaparib) 150 mg Tablet | Everest Pharmaceuticals
Olanib 150 mg (Olaparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lynparza (AstraZeneca / MSD). It belongs to the PARP inhibitor class and is used in selected ovarian, breast, pancreatic and prostate cancers.
Active ingredient: Olaparib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Megace 160 mg Alternative – Mezoxia (Megestrol acetate) 160 mg Tablet | Everest Pharmaceuticals
Mezoxia 160 mg (Megestrol acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Megace (Bristol Myers Squibb). It belongs to the progestin class and is used in certain hormone-responsive cancer settings depending on formulation and jurisdiction.
Active ingredient: Megestrol acetate
Strength: 160 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Nexavar 200 mg Alternative – Hepanib (Sorafenib) 200 mg Tablet | Everest Pharmaceuticals
Hepanib 200 mg (Sorafenib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Nexavar (Bayer). It belongs to the multikinase inhibitor class and is used in selected liver, kidney and thyroid cancers.
Active ingredient: Sorafenib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Promacta / Revolade 25 mg Alternative – Elopag (Eltrombopag) 25 mg Tablet | Everest Pharmaceuticals
Elopag 25 mg (Eltrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Promacta / Revolade (Novartis). It belongs to the thrombopoietin receptor agonist class and is used in selected immune thrombocytopenia and aplastic anemia settings.
Active ingredient: Eltrombopag
Strength: 25 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.